A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2.

Kasi Pandima Devi Mahmoud Reza PourkarimMarijn ThijssenAntoni SuredaMaryam KhayatkashaniCosmin Andrei CismaruIoana Berindan NeagoeSolomon HabtemariamSoha RazmjoueiHamid Reza Khayat Kashani

Published in: Pharmacological reports : PR (2022)

Currently, the world is facing a pandemic of the new coronavirus SARS-CoV-2 that causes COVID-19. Identifying key targets in the viral infection lifecycle is urgently needed for designing therapeutic strategies to combat the virus. Furin is a subtilisin-like proprotein convertase with diverse cellular functions. Emerging evidence suggests that furin plays a critical role in the activation and/or infectivity of SARS-CoV-2. In this perspective, we discuss the potential role of furin in the entry SARS-CoV-2 into host cells. Furthermore, we evaluate available peptide and non-peptide furin inhibitors and potential outcomes, including immune responses.

Keyphrases

sars cov
respiratory syndrome coronavirus
immune response
induced apoptosis
human health
risk assessment
metabolic syndrome
skeletal muscle
climate change
inflammatory response
signaling pathway
cell proliferation
cell death